Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction

  • Adam D. DeVore
    Duke Clinical Research Institute, Durham, NC (A.D.D., A.S.H., L.T., A.F.H.).
  • Anne S. Hellkamp
    Duke Clinical Research Institute, Durham, NC (A.D.D., A.S.H., L.T., A.F.H.).
  • Laine Thomas
    Duke Clinical Research Institute, Durham, NC (A.D.D., A.S.H., L.T., A.F.H.).
  • Nancy M. Albert
    Cleveland Clinic, OH (N.M.A.).
  • Javed Butler
    University of Mississippi Medical Center, Jackson (J.B.).
  • J. Herbert Patterson
    Eshelman School of Pharmacy, University of North Carolina, Chapel Hill (J.H.P.).
  • John A. Spertus
    Saint Luke’s Mid America Heart Institute and the University of Missouri-Kansas City, Kansas City, MO (J.A.S.).
  • Fredonia B. Williams
    Mended Hearts, Huntsville, AL (F.B.W.).
  • Carol I. Duffy
    Novartis Pharmaceuticals Corporation, East Hanover, NJ (C.I.D.).
  • Adrian F. Hernandez
    Duke Clinical Research Institute, Durham, NC (A.D.D., A.S.H., L.T., A.F.H.).
  • Gregg C. Fonarow
    Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, CA (G.C.F.).

書誌事項

タイトル別名
  • Data From CHAMP-HF

説明

<jats:sec> <jats:title>Background:</jats:title> <jats:p>Among patients with heart failure (HF) with reduced ejection fraction (EF), improvements in left ventricular EF (LVEF) are associated with better outcomes and remain an important treatment goal. Patient factors associated with LVEF improvement in routine clinical practice have not been clearly defined.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>CHAMP-HF (Change the Management of Patients with Heart Failure) is a prospective registry of outpatients with HF with reduced EF. Assessments of LVEF are recorded when performed for routine care. We analyzed patients with both baseline and ≥1 follow-up LVEF assessments to describe factors associated with LVEF improvement.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>In CHAMP-HF, 2623 patients had a baseline and follow-up LVEF assessment. The median age was 67 (interquartile range, 58–75) years, 40% had an ischemic cardiomyopathy, and median HF duration was 2.8 years (0.7–6.8). Median LVEF was 30% (23–35), and median change on follow-up was 4% (−2 to −13); 19% of patients had a decrease in LVEF, 31% had no change, 49% had a ≥5% increase, and 34% had a ≥10% increase. In a multivariable model, the following factors were associated with ≥5% LVEF increase: shorter HF duration (odds ratio [OR], 1.21 [95% CI, 1.17–1.25]), no implantable cardioverter defibrillator (OR, 1.46 [95% CI, 1.34–1.55]), lower LVEF (OR, 1.15 [95% CI, 1.10–1.19]), nonischemic cardiomyopathy (OR, 1.24 [95% CI, 1.09–1.36]), and no coronary disease (OR, 1.20 [95% CI, 1.03–1.35]).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>In a large cohort of outpatients with chronic HF with reduced EF, improvements in LVEF were common. Common baseline cardiac characteristics identified a population that was more likely to respond over time. These data may inform clinical decision making and should be the basis for future research on myocardial recovery.</jats:p> </jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ